PRTO 10.15 Proteon Therapeutics Inc. $PRTO Hit a 52 week

New Post Public Reply Private Reply Replies (0) Message Board
Emylers
PRTO 10.15 Proteon Therapeutics Inc. $PRTO Hit a 52 week low of 10.00 Currently at 10.15 -0.09 -0.88% With a day low of 10.00 and a total volume of 46,900.

PRTO Proteon Therapeutics Inc. Recent Headline News

Proteon Therapeutics Announces Pricing of Initial Public Offering
GlobeNewswire - Tue Oct 21, 6:36PM CDT
Proteon Therapeutics Inc., a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced the pricing of its initial public offering of 6,110,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts, commissions and estimated expenses. All of the shares of common stock are being offered by Proteon. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "PRTO" on October 22, 2014. In addition, Proteon has granted the underwriters a 30-day option to purchase up to 916,500 additional shares of common stock at the offering price. The offering is expected to close on October 27, 2014, subject to customary closing conditions.
PRTO: 10.15 (-0.09)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Exploring the Future of Dry Type Transformers in Global Markets

Updated Category News Views 130

The Growth of the Dry Type Transformer Market The global dry type transformer market is set to experience substantial growth, projected to rise from an estimated USD 11.72 billion in the near future to USD 16.33 billion by the end of the decade. This growth is fueled by a rising demand for reliable, sustainable, and low-maintenance power distribution solutions across...

Continue Reading
GuideWell's 2024 Impact Report Outlines Health Care Advancements

Updated Category News Views 645

GuideWell Unveils Its 2024 Impact Report Focused on Health Care GuideWell Mutual Holding Corporation recently published its annual Impact Report, shedding light on the organization's significant advancements in health care accessibility and quality. This not-for-profit entity is dedicated to reshaping how health services are delivered while putting its members and...

Continue Reading
Revolution in Automotive Security: Titan's Drone Innovation

Updated Category News Views 169

Enhancing Automotive Security with Drones In a significant advancement for automobile dealerships, Titan Protection and Consulting has successfully implemented its innovative security drone technology. This unprecedented deployment focuses on curbing theft and enhancing surveillance at automotive retail facilities. With the rise of sophisticated security solutions,...

Continue Reading
Atossa Therapeutics Announces Participation in Virtual Summit

Updated Category News Views 74

Atossa Therapeutics to Join the 2024 Maxim Healthcare Summit SEATTLE — Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company committed to developing innovative solutions in oncology, has exciting news to share. The company has announced that Michael Parks, the Vice President of Investor and Public Relations, will take part in a virtual...

Continue Reading
Investors Urged to Act Quickly in Vicor Class Action Lawsuit

Updated Category News Views 80

Investors Advised to Act Swiftly in Vicor Class Action Lawsuit Attention investors! If you've lost over $100,000 in Vicor Corporation shares, now's the time to take action. Kahn Swick & Foti, LLC (KSF), along with managing partner Charles C. Foti, Jr., a former Attorney General of Louisiana, wants to remind you of an important deadline approaching for filing lead...

Continue Reading